Adding Docetaxel to RT Improves Survival in Cisplatin-Ineligible Head & Neck Cancer
(MedPage Today) -- Adding docetaxel to radiation therapy (RT) improved survival outcomes in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, a phase III randomized trial showed. At a median follow-up of... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 4, 2023 Category: Hematology Source Type: news

CHMP recommends Bayer ’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus ADT in combination with docetaxel for marketing authorization in the European Union (EU) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). (Source: World Pharma News)
Source: World Pharma News - January 30, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

High Febrile Neutropenia Risk With Docetaxel in Prostate Cancer High Febrile Neutropenia Risk With Docetaxel in Prostate Cancer
The risk is high enough to consider routine febrile neutropenia prophylaxis in patients with metastatic castration-resistant disease. The study was published as a preprint and has not been peer reviewed.First Look (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 2, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Upfront ICIs May Enhance Second-Line Responses in NSCLC Upfront ICIs May Enhance Second-Line Responses in NSCLC
Second-line ramucirumab and docetaxel after use of immune checkpoint inhibitors may improve some outcomes for patients with NSCLC. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 8, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC
(MedPage Today) -- PARIS -- Targeted therapy in previously treated non-small cell lung cancer (NSCLC) patients harboring KRAS G12C mutations reduced the risk of disease progression or death by 34% compared with standard second-line chemotherapy... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2022 Category: Hematology Source Type: news

Gemcitabine/Docetaxel Treats Nonmuscle-Invasive Bladder Cancer
FRIDAY, Aug. 19, 2022 -- Gemcitabine plus docetaxel (Gem/Doce) may be an alternative for the treatment of high-risk non-muscle-invasive bladder cancer (NMIBC), according to a study published in the September issue of The Journal of Urology. Ian M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 19, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves Additional Indication of Nubeqa (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Nubeqa now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1 Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 5, 2022 Category: Drugs & Pharmacology Source Type: news

Eight-year data from APHINITY study show Roche ’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
Discussion on the Optimal Primary Breast Cancer Treatment. Breast Care 2019;14:103-10.[11] US Food and Drug Administration. Prescribing information for Phesgo. [Internet; cited June 2022]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf.[12] European Medicines Agency. Phesgo. [Internet; cited June 2022]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/phesgo.[13] World Health Organization. Cancer. [Internet; cited June 2022]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.[14] Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (H...
Source: Roche Media News - July 14, 2022 Category: Pharmaceuticals Source Type: news

Breakthrough spares men side effects of prostate cancer
THOUSANDS of patients with advanced prostate cancer could be spared tough chemotherapy after doctors uncovered who really benefits from it. They looked at 2,200 men given docetaxel chemo - the most common type offered to patients whose cancer has spread. (Source: Daily Express - Health)
Source: Daily Express - Health - June 18, 2022 Category: Consumer Health News Source Type: news

Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

Adding Darolutamide Ups Survival in Metastatic Prostate Cancer
WEDNESDAY, Feb. 23, 2022 -- Survival is prolonged in patients with metastatic, hormone-sensitive prostate cancer receiving darolutamide versus placebo, in combination with androgen-deprivation therapy and docetaxel, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 23, 2022 Category: Pharmaceuticals Source Type: news

Adding Darolutamide: New SOC for Metastatic Prostate Cancer Adding Darolutamide: New SOC for Metastatic Prostate Cancer
Darolutamide added onto ADT and docetaxel could be a new standard of care for men with metastatic hormone-sensitive prostate cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 19, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

The Breast Cancer With No Target May Have One: NOS The Breast Cancer With No Target May Have One: NOS
For patients with chemo-resistant, locally advanced and metastatic triple-negative breast cancer, a first-in-class agent in combination with docetaxel yielded an overall response rate of almost 46%.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news